Antisecretory Factor (AF) egg-yolk peptides reflects the intake of AF-activating feed in hens

Kaya, Ibrahim; Johansson, Ewa; Lange, Stefan; Malmberg, Per

doi:10.1016/j.yclnex.2017.01.001

Cited by 4 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The AF protein can be endogenously stimulated by either intestinal exposure to bacterial toxins or to the intake of specific food components (Bjorck et al, 2000;Lange and Lonnroth, 2001;Lonnroth et al, 1988). Furthermore, preformed AF can also be passively administered to the patient by peroral intake of Salovum, a spray dried egg yolk with a high content of the AF protein (Kaya et al 2017). The "active site" of AF, i.e.…”

Section: Introductionmentioning

confidence: 99%

High doses of Antisecretory Factor stop diarrhea fast without recurrence for six weeks post treatment

Zaman

Aamir²,

Hanson

et al. 2018

International Journal of Infectious Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

High doses of Antisecretory Factor stop diarrhea fast without recurrence for six weeks post treatment

Zaman

Aamir²,

Hanson

et al. 2018

International Journal of Infectious Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

“…Salovum® is enriched with AF peptides, among them AF-16 [16], which in experimental animal models of focal brain injury has been demonstrated to exert a significant, suppressive effect on cerebral edema with pathologically elevated ICP, and to improve cognitive function [1,6,11]. AF-16 can bypass the blood-brain barrier after iv and intranasal administration and is detected both in cerebral tissue and CSF [1,17].…”

Section: Discussionmentioning

confidence: 99%

Elevated intracranial pressure after head trauma can be suppressed by antisecretory factor—a pilot study

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background Control of intracranial pressure (ICP) is a key element in neurointensive care for directing treatment decisions in patients with severe traumatic brain injury (TBI). The anti-inflammatory protein antisecretory factor (AF) has been demonstrated to reduce experimentally induced high ICP in animal models. This report describes the first steps to investigate the uptake, safety, and influence of AF for reduction of elevated ICP in patients with TBI in a clinical setting. Method Four patients with severe TBI (Glasgow Coma Scale < 9) that required neurointensive care with ICP monitoring due to signs of refractory intracranial hypertension were investigated. One hundred milliliters of Salovum®, a commercially available egg yolk powder with high contents of AF peptides, was administrated either via nasogastric (patients 1 and 2) or rectal tube (patients 2, 3, and 4) every 8 h for 2 to 3 days as a supplement to the conventional neurointensive care. ICP was registered continuously. Plasma levels of AF were measured by enzyme-linked immunosorbent assay (ELISA) to confirm that Salovum® was absorbed appropriately into the bloodstream. Results In the first two patients, we observed that when delivered by the nasogastric route, there was an accumulation of the Salovum® solution in the stomach with difficulties to control ICP due to impaired gastric emptying. Therefore, we tested to administer Salovum® rectally. In the third and fourth patients, who both showed radiological signs of extensive brain edema, ICP could be controlled during the course of rectal administration of Salovum®. The ICP reduction was statistically significant and was accompanied by an increase in blood levels of AF. No adverse events that could be attributed to AF treatment or the rectal approach for Salovum® administration were observed. Conclusions The outcomes suggest that AF can act as a suppressor of high ICP induced by traumatic brain edema. Use of AF may offer a new therapeutic option for targeting cerebral edema in clinical practice. Keywords Traumatic brain injury. Brain edema. Intracranial hypertension. Antisecretory factor. Salovum®. AF-16 ELISA This article is part of the Topical Collection on Brain trauma

show abstract

“…Consuming SPC-flakes stimulates endogenous production of AF [ 9 ]. Salovum is a freeze-dried egg yolk powder based on eggs from hens fed with SPC-flakes and contains large amounts of AF [ 10 ]. Salovum and SPC-flakes are classified as medical food by the European Union and can be bought without a prescription in pharmacies in Sweden.…”

Section: Introductionmentioning

confidence: 99%

Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma

et al. 2023

View full text Add to dashboard Cite

Purpose Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. Despite the best available treatment, prognosis remains poor. Current standard therapy consists of surgical removal of the tumor followed by radiotherapy and chemotherapy with the alkylating agent temozolomide (TMZ). Experimental studies suggest that antisecretory factor (AF), an endogenous protein with proposed antisecretory and anti-inflammatory properties, may potentiate the effect of TMZ and alleviate cerebral edema. Salovum is an egg yolk powder enriched for AF and is classified as a medical food in the European Union. In this pilot study, we evaluate the safety and feasibility of add-on Salovum in GBM patients. Methods Eight patients with newly diagnosed, histologically confirmed GBM were prescribed Salovum during concomitant radiochemotherapy. Safety was determined by the number of treatment-related adverse events. Feasibility was determined by the number of patients who completed the full prescribed Salovum treatment. Results No serious treatment-related adverse events were observed. Out of 8 included patients, 2 did not complete the full treatment. Only one of the dropouts was due to issues directly related to Salovum, which were nausea and loss of appetite. Median survival was 23 months. Conclusions We conclude that Salovum is safe to use as an add-on treatment for GBM. In terms of feasibility, adherence to the treatment regimen requires a determined and independent patient as the large doses prescribed may cause nausea and loss of appetite. Trial registration ClinicalTrials.gov NCT04116138. Registered on 04/10/2019.

show abstract

Antisecretory Factor (AF) egg-yolk peptides reflects the intake of AF-activating feed in hens

Cited by 4 publications

References 27 publications

High doses of Antisecretory Factor stop diarrhea fast without recurrence for six weeks post treatment

High doses of Antisecretory Factor stop diarrhea fast without recurrence for six weeks post treatment

Elevated intracranial pressure after head trauma can be suppressed by antisecretory factor—a pilot study

Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma

Contact Info

Product

Resources

About